Pharma R&D changing for upcoming patent crisis

According to the Tufts Center for the Study of Drug Development, developers are "aggressively changing" R&D methods as they pursue the next blockbuster, reports in-PharmaTechnologist.

Kenneth Kaitlin, CSDD director, says the changes are necessary because of the much-debated upcoming loss of patent protection for many prescription drugs and a shortage of blockbusters in the pipeline to take their place.

"The research-based drug industry, in the United States and globally, is not sitting still, but the question remains whether developers can bring enough new drugs to market at the pace needed to remain financially viable," Kaitlin explains, as quoted by in-PharmaTechnologist.

A drugmaker can now expect to spend roughly $1.3 billion on developing a new med, according to the story. And it's become "increasingly daunting" to create blockbuster drugs that yield yearly revenue of at least $1 billion because of competition from generics and increasing R&D costs.

The solution, the Tufts researcher says, is to rely on translational science to help identify the right disease targets for new molecules and to share the risk with external partners.

- read the in-PharmaTechnologist report

Suggested Articles

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.